LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Lilly's Loxo Presents Positive Phase I/II Data In MCL At ASH
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
You may also be interested in...
CAR-Ts May Be Closer Competitors To Lilly’s Jaypirca Than Fellow BTK Inhibitors
The Loxo@Lilly drug got FDA accelerated approval in mantle cell lymphoma as the first non-covalent BTK inhibitor, enabling its use in post-BTKi disease.
Keeping Track Of Rolling Submissions: Gamida Cell, Roche, Lilly And Reata Are Latest To Use Fast Track
Applications are underway for omidubicel, mosenutuzumab, pirtobrutinib and omaveloxolone.
After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential
Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.